ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 173 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2019. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $81,765,784 | -35.9% | 2,293,570 | -17.0% | 0.08% | -31.3% |
Q2 2023 | $127,468,532 | +17.7% | 2,763,246 | +2.3% | 0.12% | +11.7% |
Q1 2023 | $108,313,175 | -13.2% | 2,701,077 | +0.2% | 0.10% | -16.3% |
Q4 2022 | $124,833,498 | +9.1% | 2,694,442 | -2.5% | 0.12% | +7.0% |
Q3 2022 | $114,408,000 | -32.4% | 2,762,822 | -2.6% | 0.12% | -27.2% |
Q2 2022 | $169,264,000 | -18.6% | 2,837,143 | -0.9% | 0.16% | +1.3% |
Q1 2022 | $207,978,000 | -11.0% | 2,863,921 | +3.1% | 0.16% | -1.9% |
Q4 2021 | $233,674,000 | +9.5% | 2,778,859 | +17.5% | 0.16% | +4.6% |
Q3 2021 | $213,355,000 | -5.6% | 2,365,621 | -0.2% | 0.15% | -3.2% |
Q2 2021 | $226,029,000 | +4.3% | 2,370,520 | +24.5% | 0.16% | -3.1% |
Q1 2021 | $216,721,000 | -16.5% | 1,903,395 | +1.5% | 0.16% | -19.4% |
Q4 2020 | $259,600,000 | +77.5% | 1,875,317 | +5.4% | 0.20% | +59.5% |
Q3 2020 | $146,214,000 | +5.8% | 1,778,978 | +0.7% | 0.13% | +0.8% |
Q2 2020 | $138,180,000 | +153.0% | 1,766,562 | +43.7% | 0.12% | +111.9% |
Q1 2020 | $54,618,000 | +7.8% | 1,229,310 | +4.6% | 0.06% | +40.5% |
Q4 2019 | $50,688,000 | -14.3% | 1,175,774 | -14.9% | 0.04% | -19.2% |
Q3 2019 | $59,112,000 | -7.6% | 1,381,777 | +37.1% | 0.05% | -5.5% |
Q2 2019 | $64,000,000 | -8.9% | 1,007,873 | -0.5% | 0.06% | -11.3% |
Q1 2019 | $70,281,000 | +60.0% | 1,013,273 | +0.3% | 0.06% | +40.9% |
Q4 2018 | $43,916,000 | -43.0% | 1,010,036 | +0.0% | 0.04% | -33.3% |
Q3 2018 | $77,094,000 | +4.9% | 1,009,872 | +5.6% | 0.07% | +10.0% |
Q2 2018 | $73,519,000 | +81.5% | 956,412 | +20.4% | 0.06% | +57.9% |
Q1 2018 | $40,516,000 | +19663.9% | 794,588 | +17877.1% | 0.04% | – |
Q4 2017 | $205,000 | -13.1% | 4,420 | -0.1% | 0.00% | – |
Q3 2017 | $236,000 | -13.6% | 4,425 | +0.6% | 0.00% | – |
Q2 2017 | $273,000 | +45.2% | 4,397 | +58.5% | 0.00% | – |
Q1 2017 | $188,000 | -5.1% | 2,775 | -1.2% | 0.00% | – |
Q4 2016 | $198,000 | +2.1% | 2,810 | +2.9% | 0.00% | – |
Q3 2016 | $194,000 | +44.8% | 2,730 | -0.1% | 0.00% | – |
Q2 2016 | $134,000 | +74.0% | 2,732 | +123.6% | 0.00% | – |
Q1 2016 | $77,000 | +305.3% | 1,222 | +618.8% | 0.00% | – |
Q4 2015 | $19,000 | – | 170 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |